Everything drug pricing and policy, every day
And the reconciliation bill is headed to a Senate vote today ... but without PBM reform or orphan-drug provisions
And IQVIA data shows the extent of the utilization management headaches for Medicare patients
And introducing a new way of segmenting the voices in the 340B debate: the (Jimmy) Buffett Rule
And the remarkable ability of hospitals to drive policy conversations in the Medicaid/reconciliation debate
And a veritable deluge of data about benefit design has me thinking about the impact on PBMs ... and patients
And the latest skirmish in the pharm-to-table trend underscores the choice that telehealth providers must make around obesity meds
And I go deep on the ideological bent of Theo Merkel, one of the point people in the MFN conversations with pharma
And what we can learn about the 340B battles to come from the fight over Medicaid cuts in the reconciliation bill
And BIO is all about AI and China, but that’s not what’s catching my eye
